BTK and myeloid sarcoma: This process followed best practice guidance in the development of narrative reviews.25 Literature searching focused on three themes using pre-defined eligibility criteria and identified evidence relating to BTK inhibition in autoimmune conditions, MS and BTK inhibitor safety profiles.